Geode Capital Management LLC Acquires 66,928 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Geode Capital Management LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 3.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,147,203 shares of the biopharmaceutical company's stock after purchasing an additional 66,928 shares during the quarter. Geode Capital Management LLC owned 1.66% of Alnylam Pharmaceuticals worth $589,209,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Huntington National Bank increased its stake in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 45 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $26,000. Washington Trust Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter worth approximately $42,000. Finally, True Wealth Design LLC raised its holdings in shares of Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 153 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,752 shares of the firm's stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares in the company, valued at $3,941,955. This trade represents a 10.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the company's stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock valued at $2,540,455 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on ALNY. Raymond James lifted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a research report on Friday, November 1st. Barclays lifted their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a report on Friday, November 1st. Canaccord Genuity Group increased their price objective on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Cantor Fitzgerald restated a "neutral" rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Finally, William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $298.09.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock traded up $0.18 during trading hours on Friday, reaching $245.44. 590,299 shares of the company were exchanged, compared to its average volume of 860,965. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a 50-day moving average of $267.01 and a 200 day moving average of $248.16. The firm has a market cap of $31.66 billion, a price-to-earnings ratio of -93.68 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analysts' expectations of $532.91 million. Alnylam Pharmaceuticals's revenue was down 33.3% on a year-over-year basis. During the same period last year, the company posted $1.15 earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.